Anchiano Therapeutics Ltd. - American Depositary Share (ANCN): Price and Financial Metrics


Anchiano Therapeutics Ltd. - American Depositary Share (ANCN)

Today's Latest Price: $1.55 USD

0.02 (-0.96%)

Updated Jul 8 9:46am

Add ANCN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 337 in Biotech

See all "A" rated Strong Buy stocks

ANCN Daily Price Range
ANCN 52-Week Price Range

ANCN Stock Price Chart Technical Analysis Charts


ANCN Price/Volume Stats

Current price $1.55 52-week high $4.74
Prev. close $1.56 52-week low $0.51
Day low $1.55 Volume 472
Day high $1.55 Avg. volume 45,161
50-day MA $1.21 Dividend yield N/A
200-day MA $1.41 Market Cap 11.46M

Anchiano Therapeutics Ltd. - American Depositary Share (ANCN) Company Bio


Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.


ANCN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ANCN Latest Social Stream


Loading social stream, please wait...

View Full ANCN Social Stream

Latest ANCN News From Around the Web

Below are the latest news stories about Anchiano Therapeutics Ltd that investors may wish to consider to help them evaluate ANCN as an investment opportunity.

Anchiano Appoints Stan Polovets as Chairman of the Board

Anchiano Therapeutics Ltd. (ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of directors. Mr. Polovets joined the board of Anchiano in April 2020. “We warmly welcome Stan as our new Chairman,” said Frank G. Haluska, M.D., Ph.D., President and Chief Executive Officer of Anchiano.

Yahoo | May 26, 2020

Anchiano Therapeutics Reports First Quarter 2020 Financial Results

CAMBRIDGE, Mass., May 11, 2020 -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a preclinical biopharmaceutical company dedicated to the discovery and development of.

Yahoo | May 11, 2020

Anchiano Appoints Steve DiPalma as Chief Financial Officer

Anchiano Therapeutics Ltd. (ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPalma has served as a Senior Financial Advisor to Anchiano by agreement with Danforth Advisors since 2018; he will succeed Jonathan Burgin, who is leaving the Company as part of the planned closure of the Company’s Israel offices and facilities.

Yahoo | May 5, 2020

Anchiano to Hold Virtual Annual Meeting of Shareholders

Anchiano Therapeutics Ltd. (ANCN) (the “Company”) today announced it has elected to hold its 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) as a virtual meeting due to the ongoing public health concerns related to the coronavirus (COVID-19) pandemic. As described in the proxy materials for the Annual Meeting (the “Proxy Materials”), shareholders as of the close of business on March 23, 2020, the record date, are entitled to participate in the Annual Meeting. Shareholders can participate in the Annual Meeting via the internet by visiting https://anchiano.webex.com/anchiano/j.php?MTID=m99b0b42faed9b725d14a1b66c65252b7 and entering the meeting number (280 326 067).

Yahoo | April 17, 2020

Anchiano Therapeutics Reports Year-End 2019 Financial Results

Entered into an exclusive worldwide collaboration and option to license agreement on September 20, 2019 with ADT Pharmaceuticals, LLC (“ADT”) to develop novel small-molecule pan-RAS inhibitors and PDE10/β-catenin inhibitors aimed at difficult-to-treat, genetically-defined cancers, underscoring Anchiano’s focus on developing therapies with targeted approaches. Anchiano believes that successful development of its pan-RAS-targeted therapy, with activity regardless of RAS isoform or mutation, has the potential for significant clinical impact across a variety of tumor types including lung, colorectal, pancreatic, melanoma and bladder cancer, and represents a substantial commercial opportunity.

Yahoo | March 18, 2020

Read More 'ANCN' Stories Here

ANCN Price Returns

1-mo 34.67%
3-mo 121.21%
6-mo 6.16%
1-year -64.93%
3-year N/A
5-year N/A
YTD 10.71%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.817 seconds.